Assenagon Asset Management S.A. Increases Position in Gilead Sciences, Inc. $GILD

Assenagon Asset Management S.A. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 91.9% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 512,436 shares of the biopharmaceutical company’s stock after buying an additional 245,382 shares during the period. Assenagon Asset Management S.A.’s holdings in Gilead Sciences were worth $71,418,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter valued at $26,000. Wealth Preservation Advisors LLC boosted its stake in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer, expanding the drug’s addressable market and strengthening Gilead’s oncology growth story. U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
• Positive Sentiment: Merck also received FDA approval for KEYTRUDA combinations that include Trodelvy, which could increase Trodelvy’s use in combination regimens and support broader adoption. FDA Approves KEYTRUDA combinations with Trodelvy
• Positive Sentiment: Gilead also received European Commission approval to expand Trodelvy’s label in metastatic TNBC, further widening the drug’s commercial opportunity outside the U.S. Gilead Wins EC Approval to Expand Trodelvy’s Label in Metastatic TNBC
• Neutral Sentiment: Short-interest data showed no meaningful change, so it does not appear to be a major driver of the stock’s move.
• Negative Sentiment: Despite the Trodelvy approvals, Gilead’s shares still dipped versus the broader market, suggesting investors may be taking profits or focusing on broader market weakness rather than the regulatory upside. Gilead Sciences Dips More Than Broader Market: What You Should Know

Gilead Sciences Trading Down 1.1%

Shares of GILD stock opened at $123.84 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a twelve month low of $105.79 and a twelve month high of $157.29. The company’s 50-day moving average price is $130.42 and its 200-day moving average price is $134.33. The stock has a market cap of $153.76 billion, a price-to-earnings ratio of 16.87 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the business earned $1.81 earnings per share. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GILD shares. Rothschild & Co Redburn reduced their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Citigroup boosted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Truist Financial reaffirmed a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Finally, Jefferies Financial Group assumed coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $158.41.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the transaction, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,000 shares of company stock worth $8,930,150 in the last 90 days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.